Leserbrief zum Beitrag: COPD – Dreifachtherapie senkt Exazerbationsrate

• Literatur

• 1 Lipson DA, Barnhart F, Brealey N. et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med 2018; 378: 1671-1680
• 2 Wedzicha JA, Banerji D, Chapman KR. et al. Indacaterol-Glycopyrronium vs. Salmeterol-Fluticason for COPD. N Engl J Med 2016; 374: 2222-2234
• 3 Magnussen H, Disse B, Rodriguez-Roisin R. et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371: 1285-1294
• 4 Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67: 957-963
• 5 Vestbo J, Anderson JA, Brook RD. et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016; 387: 1817-1826